KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novavax (NVAX) Gains from Sales and Divestitures (2019 - 2020)

Historic Gains from Sales and Divestitures for Novavax (NVAX) over the last 4 years, with Q3 2020 value amounting to $781812.0.

  • Novavax's Gains from Sales and Divestitures rose 97632.75% to $781812.0 in Q3 2020 from the same period last year, while for Sep 2020 it was $781812.0, marking a year-over-year increase of 97632.75%. This contributed to the annual value of $72637.0 for FY2019, which is N/A changed from last year.
  • Novavax's Gains from Sales and Divestitures amounted to $781812.0 in Q3 2020, which was up 97632.75% from $47563.0 recorded in Q2 2020.
  • In the past 5 years, Novavax's Gains from Sales and Divestitures ranged from a high of $781812.0 in Q3 2020 and a low of $17563.0 during Q1 2020